Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

International Stem Cell Q3 2026 Results: Net Income $21.8M, Up 38107.0% YoY

International Stem Cell Corporation reported a significant net income of $21.5 million for the nine months ended September 30, 2026, primarily driven by a $24.0 million gain from discontinued operations following the sale of a business. The company's cash position strengthened to $20.0 million, while it continued to experience operating losses from its continuing stem cell research and product sales activities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.2
Net income21.80.1
EPS (diluted, $ a share)$1.40$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+38107.0%
Revenue, year on year-10.9%
Source

10-Q filed with the SEC, OTC: ISCO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

International Stem Cell Corp: key numbers

Share price
$0.1700Close, Nov 20
Market cap
$1.39M
Shares outstanding
8.16MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.